Plasma cells: a feasible therapeutic target in pulmonary fibrosis?

Competing Interests: Conflict of interest: A.T. Goodwin has received research funding from an Asthma + Lung UK Malcolm Weallens Pulmonary Fibrosis grant and a Medical Research Council clinical training fellowship, in addition to conference travel grants from the British Association for Lung Research and the British Thoracic Society. P.W. Noble sits on the scientific advisory boards of Pliant Therapeutics and Lasson Therapeutics; he has received prior honoraria payments from Boehringer Ingelheim and Genentech/Roche and owns stocks in Pliant Therapeutics. A.L. Tatler is a co-investigator on an MRC Programme Grant and a Cystic Fibrosis Foundation project grant; additionally, she acts as a consultant to Pliant Therapeutics and Accession Therapeutics; she has received honoraria from the Universities of Edinburgh, Southampton and Hull (in the past three years) for PhD examination services and speaker fees from the Australasian Rare Lung Disease Conference in 2021.